Phenotypes associated with this allele

• Allele Symbol: Fkbpl^{tm1.1(KOMP)Wtsi}
• Allele Name: targeted mutation 1.1, Wellcome Trust Sanger Institute
• Allele ID: MGI:5558157
• Summary: 4 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Fkbpl^tm1.1(KOMP)Wtsi/Fkbpl^tm1.1(KOMP)Wtsi	C57BL/6N-Fkbpl^tm1.1(KOMP)Wtsi/MbpMmucd	MGI:6480455
hm2	Fkbpl^tm1.1(KOMP)Wtsi/Fkbpl^tm1.1(KOMP)Wtsi	C57BL/6N-Fkbpl^tm1.1(KOMP)Wtsi/Ucd	MGI:6262447
hm3	Fkbpl^tm1.1(KOMP)Wtsi/Fkbpl^tm1.1(KOMP)Wtsi	involves: C57BL/6N * C57BL/6NTac	MGI:5770095
ht4	Fkbpl^tm1.1(KOMP)Wtsi/Fkbpl^+	involves: C57BL/6N * C57BL/6NTac	MGI:5770094

Genotype
MGI:6480455

hm1

• Allelic Composition: Fkbpl^{tm1.1(KOMP)Wtsi}/Fkbpl^{tm1.1(KOMP)Wtsi}
• Genetic Background: C57BL/6N-Fkbpl^{tm1.1(KOMP)Wtsi}/MbpMmucd
• Cell Lines: EPD0466_1_C01

Data Sources

IMPC Data for Fkbpl

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

preweaning lethality, complete penetrance ( J:211773 )

IMPC - UCD

Genotype
MGI:6262447

hm2

• Allelic Composition: Fkbpl^{tm1.1(KOMP)Wtsi}/Fkbpl^{tm1.1(KOMP)Wtsi}
• Genetic Background: C57BL/6N-Fkbpl^{tm1.1(KOMP)Wtsi}/Ucd
• Cell Lines: EPD0466_1_C01

Data Sources

IMPC Data for Fkbpl

mortality/aging

embryonic lethality prior to tooth bud stage ( J:211773 )

IMPC - TCP

embryonic lethality prior to organogenesis ( J:211773 )

IMPC - TCP

Genotype
MGI:5770095

hm3

• Allelic Composition: Fkbpl^{tm1.1(KOMP)Wtsi}/Fkbpl^{tm1.1(KOMP)Wtsi}
• Genetic Background: involves: C57BL/6N * C57BL/6NTac
• Cell Lines: EPD0466_1_C01

mortality/aging

embryonic lethality, complete penetrance ( J:226964 )

• heterozygous intercrosses fail to yield any homozygotes, with embryonic lethality occurring before E8.5

Genotype
MGI:5770094

ht4

• Allelic Composition: Fkbpl^{tm1.1(KOMP)Wtsi}/Fkbpl⁺
• Genetic Background: involves: C57BL/6N * C57BL/6NTac
• Cell Lines: EPD0466_1_C01

cardiovascular system

abnormal tumor vascularization ( J:226964 )

• following intradermal implantation of Lewis lung carcinoma (LLC) tumors, heterozygotes show an increase in CD31-stained blood vessels with the endothelium appearing thicker and less organized than in similarly-treated wild-type controls, indicating enhanced tumor angiogenesis

abnormal vascular branching morphogenesis ( J:226964 )

• in an ex vivo aortic ring assay, heterozygous mutant aortae show an enhanced pattern of sprouting with a significant increase in average vessel length relative to wild-type aortae

increased angiogenesis ( J:226964 )

• in an ex vivo aortic ring assay, heterozygous mutant aortae show enhanced sprouting of vessels relative to wild-type aortae

• in an in vivo sponge assay, bFGF-treated polyether sponges implanted in mutant mice show a significantly higher number (15% to 20%) of endomucin-stained vessels relative to wild-type controls

neoplasm

abnormal tumor vascularization ( J:226964 )

• following intradermal implantation of Lewis lung carcinoma (LLC) tumors, heterozygotes show an increase in CD31-stained blood vessels with the endothelium appearing thicker and less organized than in similarly-treated wild-type controls, indicating enhanced tumor angiogenesis

increased tumor growth/size ( J:226964 )

• following intradermal implantation of LLC tumors, LLC cells grown on the rear dorsum of heterozygous mutant mice show an increased growth rate relative to those in similarly-treated wild-type controls

mortality/aging

increased susceptibility to induced morbidity/mortality ( J:226964 )

• following intradermal implantation of LLC tumors, heterozygotes show a significantly shorter survival (defined as time to reach >600 mm3 in tumor volume) than similarly-treated wild-type controls